The post Moderna, Merck cancer vaccine reduces risk of skin cancer return appeared on BitcoinEthereumNews.com.

An exterior view of Moderna’s clinical manufacturing facility.  David L. Ryan | Boston Globe | Getty Images Moderna and Merck‘s experimental cancer vaccine, when used in combination with Merck’s blockbuster therapy Keytruda, reduced the risk of death or relapse in patients with the most deadly form of skin cancer after three years, according to midstage trial data released Thursday.  The combination specifically slashed the risk of death or recurrence of the cancer, known as melanoma, by 49% in patients in later stages of the disease compared to those who received Keytruda alone after three years. The cancer vaccine in combination with Keytruda also reduced the risk of melanoma spreading to other parts of the body by 62%. Those results build on midstage trial data the companies released earlier this year, which showed the efficacy of the combination in the same 157 patients over a shorter period. After around two years, the vaccine and Keytruda cut the risk of death or relapse by 44% in melanoma patients, and reduced the risk of the cancer spreading in the body by 65%, according to the earlier trial data.  The most common side effects of the vaccine after three years were fatigue, injection site pain and chills, according to Thursday’s data. The new results suggest that the cancer shot used with the immunotherapy continues to provide meaningful health benefits to melanoma patients after they stay on the treatment for a longer period of time. The two drugmakers are continuing to study the combination as a treatment for melanoma in a late-stage trial, which began in July. The vaccine, which uses the same mRNA technology as Moderna’s Covid vaccine, is custom-built based on an analysis of a patient’s tumors after surgical removal. The shot is designed to train the immune system to recognize and attack…

---

Filed under: News - @ December 14, 2023 1:18 pm